Quilla, Delia A.
HRN: 22-12-15 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/30/2022
CO-AMOXICLAV 625MG (TAB)
10/30/2022
11/06/2022
PO
1 Tab
BID
Soft Tissue Injury
Waiting Final Action
Indication: Empiric Type of Infection: Skin & Soft Tissue Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes